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Case Report 
Pediatric TPN: Efficacy and Toxicity of a New Fat Emulsion 
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ABSTRACT. Fat emulsions are particularly valuable in pedi- 
atric total parented nutrition (TPN) because they provide an 
isotonic solution rich in calories. Little is known about the ideal 
composition of fatty acid emulsions, however, and very few 
formulations are commercially available. A new fat emulsion 
using a safflower oil base has recently been apjroved. We have 
Intravenously administered fat emulsions are now 
widely used in programs of total paren ted  nutrition 
(TPN). In addition to providing essential fatty acids, 
they offer a concentrated energy source in an isotonic 
solution. These properties make them particularly useful 
in the pediatric population in whom glucose intolerance 
and renal function limitations may contraindicate the 
sole use of large volume glucose and amino acid (AA) 
solutions for intravenous (IV) nutrition.’ In concentra- 
tions that can be tolerated by peripheral veins, glucose 
and AA solutions alone cannot provide adequate calories 
for growth without the use of prohibitively large volumes. 
However, the addition of a fat emulsion which provides 
up to 20 to 50% of the caloric requirements makes pe- 
ripherally administered TPN more widely applicable?. 
Fat emulsions using soybean or cottonseed oil as the 
major lipid source have been used clinically. The most 
widely used product in this country has been a 10% 
soybean oil emulsion (Intralipid). The cottonseed prep- 
aration has been used in Europe. We have recently tested 
a new 10% safflower oil emulsion (Liposyn, Abbott Lab- 
oratories) in a small group of pediatric patients. Using 
this new emulsion as a major caloric source in TPN, this 
study has evaluated weight changes, routine laboratory 
findings, changes in nutritional status, and side effects 
during 21 days of treatment in 4 children ranging in age 
from 1 to 15 years. 
MATERIALS AND METHODS 
The study was conducted in Mott.Children’s Hospital, 
University of Michigan Medical Center, Ann Arbor, 
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used this new emulsion to provide a significant percentage of 
the nonprotein caloric requirements (24 to 42%) in 4 patients 
requiring TPN. These patients ranged in age from 1 to 15 years 
and received no enteral nutrition during the 3-week course of 
the study. Nutritional improvement without major toxic effects 
was documented in each patient. 
Michigan, during February, March, and April 1979. Chil- 
dren under age 16 requiring TPN for a t  least 21 days 
were candidates for the study. Patients receiving any 
enteral nutrition, and those with liver damage, renal 
failure, or massive systemic infection were excluded. Four 
patients completed the study. Their histories are sum- 
marized below and their nutritional assessments are sum- 
marized in Table I. 
Patient 1 is a 7-year-old white female with ulcerative 
colitis who was admitted for weight loss and diarrhea. 
Seven months previously she had undergone a subtotal 
colectomy, endorectal pull-through and loop ileostomy. 
Five months before admission her ileostomy was closed. 
Patient 2 is a 1-year-old white male born with a tra- 
cheoesophageal fistula. Primary repair was attempted a t  
another hospital, but was complicated by an anastomotic 
disruption which was treated with a feeding gastrostomy 
and a cervical esophagostomy. He underwent esophageal 
replacement with a colon interposition 3 days prior to 
initiation of TPN therapy. 
Patient 3 is a 15-year-old white male with Crohn’s 
disease who was admitted for hypoproteinemia and 
marked edema. He had done well on medical manage- 
ment for 3% years until shortly before this admission. 
Patient 4 is a 15-year-old white male who is presumed 
cured of his stage 1A Hodgkins disease treated 7 years 
before admission. An episode of Hemophilus influenzae 
meningitis 2 years before admission left him with a 
neurogenic bladder. He was admitted for vomiting and 
weight loss of unknown origin. 
Parental informed consent was obtained and additional 
subject consent was received from children over 7 years 
old. The following preinfusion tests were performed: uri- 
nalysis, complete blood count with differential white 
blood cell count, platelet count, serum electrolytes, urea 
nitrogen, creatinine, glucose, calcium, phosphorus, uric 
acid, albumin, total protein, cholesterol, triglycerides, 
total bilirubin, alkaline phosphatase, LDH, and SGOT. 
Subclavian vein catheterization. was carried out in pa- 
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tients 1,3,  and 4. In patient 2, peripheral venous access 
was established. All 4 patients were begun on a TPN 
program of glucose, AA and the new safflower oil emul- 
sion. The emulsion was infused through a Y-connector 
into the line containing the glucose-AA solution and the 
infusion was continuously administered during each 24- 
hr period for 21 days. 
A typical solution used for centrally administered TPN 
consisted of 25% glucose and 3.5% AA (Aminosyn, Abbott 
Laboratories). The peripheral regimen consisted of 12.5470 
glucose and 2.5470 AA. The TPN solution also contained 
routine vitamin and mineral additives which are sum- 
marized in Table 11. 
Each 100 ml of the new fat emulsion contains 10 g 
safflower oil, 1.2 g emulsifying agent egg phosphatide, 1.2 
g glycerin to make the emulsion isotonic (340 mOsm/L), 
and is adjusted to a pH between 5.0 and 9.0. The solution 
provides 1.11 kcal/ml. The fatty acid composition of this 
oil is compared to that of soybean and cottonseed oils in 
Table 111.4 
Table IV summarizes the TPN treatment of these 4 
children, and includes calculations of the amount of 
various nutrients provided. Daily observations included 
vital signs, weight, and a report of adverse symptoms or 
sidi' effects. Estimated caloric requirements were com- 
puted daily and compared to calories actually given. At 
weekly intervals, the initial battery of blood and urine 
tests were repeated and an assessment was made of any 
changes in the patient's nutritional status. 
RESULTS 
Each patient survived the observation period and 
showed clinical improvement. Daily weight information 
is summarized in Figure 1. Patient 1 showed a weight 
gain of 3.1 kg over the 3 week period and her strength 
improved markedly. Her initially loW serum albumin and 
total lymphocyte counts showed no significant change, 
however. Patient 2 showed stable weight maintenance 
despite increased demands secondary to pneumonia 
which required assisted endotracheal ventilation. He did 
not, however, receive sufficient calories for growth, due 
to the limitations on total calorie infusion with a periph- 
eral line. His serum albumin, which was initially low, did 
not change significantly. Patient 3 gained 5 kg during the 
study. His edema resolved as his serum albumin in- 
creased from 1.8 to 3.0 6% and his very low total lympho- 
cyte count improved only slightly from 115 to 133. Patient 
4 gained 6.8 kg and his initially normal laboratory finding 
remained unchanged. 
The patients were closely monitored for any signs of 
toxicity. Each episode of nausea, vomiting, chills, or 
headache was noted. No such symptoms were attributed 
to the fat emulsion infusion. Patient 3 had fever second- 
TABLE I 
Initial nutritional assessments 
Patient 
1 2 3 4 
Height percentile 35th t 5 t h  5th 65th 
Weight percentile 5th t c 5 t h  5th 25th 
Serum albumin (g%) 3.8 2.7 1.8 3.7 
Total lymphocyte count 1360 4032 115 2278 
TABLE I1 
Guidelines for TPN additices 
Constituent Amt k d 2 4  hr hIaximum/24 hr 
Heparin 100 IU" 500 IU/liter 
Sodium 2-4 mEq 150 mEq 
Potassium 2-3 mEq 240 mEq 
Chloride 2-4 mEq 120 mEq 
Magnesium 0.6 mEq 24 mEq 
Calcium 1.0 mEq 11 mEq 
Phosphate 3.5 mm ' 50mm 
hlVIb 0.5 ml 2.5 ml 
Folic acid 0.5 mg 
Trace elements' 0.3 ml 0.3 ml 
Iron, vitamin B12, As needed parenterally 
vitamin K 
a International units. 
MVI concentrate (US.  Pharmaceutical Corporation): Each 5 ml 
contains: ascorbic acid, 500 mg; vitamin A, 10,OOO IU; vitamin D, 1,OOO 
IU; thiamine, 50 mg; riboflavin, 10 mg; pyridoxine, 15 mg; niacin, 100 
mg; Dexpanthenol, 25 mg; vitamin E, 5 IU. 
Trace element solution (hlanufactured at University of Michigan 
Pharmacy Dept.) Each ml contains: zinc, 2 mg (0.060 mEq); copper, 0.4 
mg (0.030 mEq); manganese, 0.2 mg (0.015 mEq); iodide, 0.056 mg 
(O.OOO44 mEq). 
TABLE I11 
Fatty acid composition of the oils in faf  emulsions 
Cottonseed Soybean Safflower 
Linoleic acid" 45% 54% 79% 
Oleic acid 30 26 12 
Palmitic acid 22 9 7 
Linolenic acid 8 
Other fatty acids 3 3 2 
Essential fatty acid. 
TABLE IV 
Auerage daily nutritional components 
Patient 
1 2 3 4 
Route of administra- 




Total volume (cc/kg) 
Volume of fat emul- 
sion (cc) 







protein calorie ratio 
Central Peripheral Central 
17.8 6.5 47.4 
80 100 45 
100.4 88 54.2 
108 151 54 
504 183 503 
42% 37% 29% 
2.82 2.85 1.1 
2.7 2.3 1.5 











ary to his pneumonia. Patient 4 complained of nausea, 
vomiting, chills, and headache prior to and throughout 
the course of the study. These symptoms decreased in 
frequency and severity during therapy. He developed a 
significant fever on the 16th day of infusion which was 
thought to be related to his central venous catheter. 
Though no culture evidence of infection was found, the 
fever resolved following discontinuance of his old CVP 
and insertion of a new central line. 
No significant toxicity was noted by laboratory exam- 
inations. Hypertriglyceridemia in the range of 1.5 to 2 
times normal values was seen in all the patients. Patient 
3 and 4 had only transient elevations which returned to 
normal by the end of the study. The younger patients (1 
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FIG. 1. Daily weights. 
and 2) showed significant elevations initially, followed by 
gradually declining values. Serum cholesterol levels were 
all normal a t  the completion of the study and showed 
only mild early elevations of 15% above normal in pa- 
tients l and 2. Serum urea nitrogen remained normal in 
all the subjects. Serum GOT levels showed an initial 
elevation to approximately twice normal followed by a 
return toward normal. Three of four subjects showed an 
actual decline of LDH and alkaline phosphatase levels 
during the study. Patient 1 showed a small increase in 
LDH and patient 2 had a small increase in alkaline 
phosphatase. Serum bilirubin remained normal in all the 
patients. 
DISCUSSION 
The practice of using fat as a component of TPN is 
well accepted. However, a wide variation in the biological 
activity of various fat emulsions makes it difficult to 
generalize about safety or effectiveness? The effects of 
different fatty acid combinations are not fully known. 
The new safflower oil emulsion may offer a theoretical 
advantage since it contains a higher percentage of the 
essential fatty acid linoleic acid than previously available 
oil emulsions, It does not contain the linolenic acid found 
in small amounts in soybean oil emulsions. Structures 
related to linolenic acid are found in some human tissues, 
but there is no conclusive evidence that linolenic acid is 
essential to man’s diet? This area needs further investi- 
gation. 
This study does not show isolated effects of the new 
safflower oil emulsion, since it was given in a multiple- 
nutrient program of TPN. Changes in liver function tests 
similar to those observed in our patients have been 
frequently noted during TPN with or without a fat emul- 
~ i o n . ~  Changes in serum cholesterol with different oils 
have been variable, and the small, transient elevations 
noted in this study are consistent with previous findings 
for other preparations.8. The mild serum triglyceride 
elevations seen as the body processes this exogenous oil 
are expected. None of the patients exhibited signs of the 
“overloading syndrome” seen with some other prepara- 
tions, especially cottonseed oil products.” None exhibited 
any clinical signs of essential fatty acid deficiency. 
It can be concluded that no serious side effects or 
toxicity occurred in this small group of children who 
received a significant percentage (24 to 42%) of their 
nonprotein caloric requirements from a new safflower oil 
emulsion. They all maintained or gained weight, and 
improved clinically during the 3-week study period. 
These early results suggest that this safff ower oil emul- 
sion is safe and effective, and deserves further use and 
evaluation. 
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